Diabetic Nephropathy Clinical Trial
Official title:
Clinical Research of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) in the Treatment of Diabetic Nephropathy
Diabetic nephropathy (DN) is one of the most serious complications of diabetes and the leading cause of end-stage chronic kidney disease. DN is a refractory disease with low awareness, high incidence, and high disability. The incidence of DN can reach 30 to 40% after 20 years of diabetes, of which 5~10% of patients will progress to end-stage renal disease, and epidemiological surveys predict that by 2030, DN will become the seventh leading cause of death in the world. Currently, there are no effective drugs for treating DN. This clinical trial is to inspect the safety and efficiency of human umbilical cord mesenchymal stem cells (UC-MSCs) therapy for patients with DN.
Diabetic nephropathy (DN) is one of the most important microvascular complications of
diabetes. It is a persistent and refractory disease. There is currently a lack of effective
clinical treatments for DN. The basic pathological processes of DN are renal tissue cell
damage, apoptosis and continuous increase of inflammatory cytokines induced by early high
glucose, which gradually leads to glomerular sclerosis and renal fibrosis.
Human umbilical cord mesenchymal stem cells (UC-MSCs), as the "youngest" adult stem cells,
have powerful anti-inflammatory functions, stronger differentiation potential, and good
safety. They are ideal seed cells for the treatment of DN. At present, studies on a variety
of animal models of DN have shown that mesenchymal stem cell transplantation can delay the
progression of DN and have a certain repair effect on damaged kidney tissue and renal
function. Our previous preclinical study showed that UC-MSCs effectively improved the renal
function, inhibited inflammation and fibrosis, and prevented its progression in a rat model
of diabetes-induced chronic renal injury. Some autologous or allogeneic mesenchymal stem
cells have been carried out abroad treatment of chronic kidney disease caused by various
reasons, including clinical trials of DN, phase I/II test results did not show obvious
adverse reactions related to stem cell therapy, and can improve the patient's renal function
and quality of life to a certain extent.
The purpose of this study is to investigate efficiency and safety of UC-MSCs in treating DN
patients. This trial will recruit 38 patients. 19 patients received the treatment of
conventional treatment + equal volume normal saline containing 1% human albumin (placebo
group) were used as control group; conventional treatment + 1*10E6 UC-MSCs/kg body weight
(experimental group) for intravenous infusion (once a week, 3 times in total) to treat 19
patients with DN (by unified standard inclusion), and subjects will be followed a total of 48
weeks from time of initial cell treatment.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT03658317 -
Renal Resisitive Index as an Indicator of the Progression of Diabetic Nephropathy
|
N/A | |
| Recruiting |
NCT02501772 -
The Evaluation of Effect of Sanyinjiao (SP6) Acupressure on Early Diabetic Nephropathy
|
N/A | |
| Completed |
NCT02276196 -
Effect of LIXIsenatide on the Renal System
|
Phase 4 | |
| Completed |
NCT02829177 -
Microalbuminuria and Allopurinol in Type 1 Diabetes
|
Phase 4 | |
| Completed |
NCT02251067 -
Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients
|
Phase 2 | |
| Completed |
NCT01440257 -
A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria
|
Phase 2 | |
| Active, not recruiting |
NCT01273675 -
An Investigation on the Effect of Candesartan on Early Diabetic Nephropathy
|
N/A | |
| Terminated |
NCT01129557 -
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
|
Phase 4 | |
| Completed |
NCT00317954 -
Spironolactone in Diabetic Nephropathy
|
Phase 4 | |
| Active, not recruiting |
NCT02237352 -
Mechanisms of Diabetic Nephropathy in Ecuador
|
||
| Not yet recruiting |
NCT05061459 -
The Expression of circANKRD36 as a New Biomarker of Diabetic Nephropathy
|
||
| Completed |
NCT01935167 -
To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy
|
Phase 2 | |
| Recruiting |
NCT01673204 -
Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy
|
Phase 4 | |
| Completed |
NCT01726816 -
Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy
|
Phase 2 | |
| Recruiting |
NCT01458158 -
Matrix Metalloproteinases in Atherosclerosis of Chronic Kidney Disease
|
N/A | |
| Completed |
NCT01447147 -
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
|
Phase 2 | |
| Completed |
NCT01476501 -
Vitamin D Supplementation in Diabetic Nephropathy
|
Phase 2 | |
| Completed |
NCT01003236 -
Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic Nephropathy
|
Phase 2 | |
| Completed |
NCT00535925 -
Nephropathy In Type 2 Diabetes and Cardio-renal Events
|
Phase 4 | |
| Completed |
NCT00097955 -
Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria
|
Phase 2 |